retatrutide type 2 diabetes trial results 2024 2025 🚨Breaking: Retatrutide's first Phase 3 T2D data just dropped. ▸ A1C: −2.0% at 40 weeks ▸ Weight: −36.6 lbs (−16.8%) at 12 mg ▸ No weight loss plateau — curve still descending Therapeutic Potential of GLP-1 Type:Paperback Dietary Concern_High Protein (15g+)

retatrutide type 2 diabetes trial results 2024 2025 🚨Breaking: Retatrutide's first Phase 3 T2D data just dropped. ▸ A1C: −2.0% at 40 weeks ▸ Weight: −36.6 lbs (−16.8%) at 12 mg ▸ No weight loss plateau — curve still descending Therapeutic Potential of GLP-1 Type:Paperback Dietary Concern_High Protein (15g+)

Therapeutic Potential of GLP-1 Receptor Agonists in Diabetes and Cardiovascular Disease: Mechanisms and Clinical Implications | Cardiovascular Drugs and Therapy | Springer Nature Link

For patients exploring GLP-1 treatment options, understanding the full cost structure—including consultation fees, medication formulation type, and whether genetic or biomarker data might inform dosing—is essential for making informed decisions

Dietary Concern_High Protein (15g+)

Type:Paperback

Swelling: Swelling of the face, lips, tongue, or throat is a sign of a severe allergic reaction